People with localized scleroderma, or morphea, are more likely to develop cancer than the general population. This is a rare autoimmune skin disease in which the immune system attacks the body's own tissues, causing patches of hardened skin due to excessive collagen accumulation. Researchers at McGill University in Canada reached this conclusion. The findings were published in JAMA Dermatology.

The scientists analyzed medical data from 6,181 patients with morphea and 8,133 people with systemic scleroderma. The data covered the period from 1996 to 2019, with patient follow-up continuing through 2020.

During the study, cancer developed in 12.65% of patients with localized scleroderma and 13.57% of those with the systemic form of the disease. Cancer incidence in the first group was 24% higher than expected for people of the same age and sex in the general population, compared with 37% higher in the second group.

Breast cancer and cancers of the female reproductive system were diagnosed more frequently in patients with morphea. Lung cancer was the most common cancer among those with systemic scleroderma. The relative increase in risk was particularly pronounced among younger patients.

The authors note that localized scleroderma has traditionally been viewed primarily as a skin disease, so its possible association with cancer has received insufficient attention. However, the study identified a statistical association and does not prove that morphea directly causes tumors. The use of immunosuppressants was associated with a lower incidence of cancer in both groups, although the reasons for this pattern remain unclear.